⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9163785 | 0.99 | — | — | |
| SCHEMBL9162892 | 0.94 | — | — | |
| SCHEMBL9164497 | 0.93 | — | — | |
| SCHEMBL9159431 | 0.91 | — | — | |
| SCHEMBL9162732 | 0.91 | EGFR (0.39) | — | |
| SCHEMBL9165218 | 0.89 | — | — | |
| SCHEMBL9166275 | 0.87 | — | — | |
| SCHEMBL9161107 | 0.86 | — | — | |
| SCHEMBL9090645 | 0.85 | P2RX7 (0.39) | — | |
| SCHEMBL9164923 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0354994-B1 | Quinoline derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-01-25 | — | — | EP | claimed |
| US-5254565-A | Enzyme inhibitors; anticholesterol agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-19 | — | — | US | claimed |
| EP-0354994-A2 | Quinoline derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-02-21 | — | — | EP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0354994-B1 | Quinoline derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5254565-A | Enzyme inhibitors; anticholesterol agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-19 | — | — | US | disclosed |
| EP-0354994-A2 | Quinoline derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-02-21 | — | — | EP | disclosed |